August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery” 37 citations
,
September 2002 in “Acta pædiatrica” A cystic fibrosis patient developed Cushing's syndrome from a drug interaction between itraconazole and budesonide, which improved after stopping the medications.
61 citations
,
January 2015 in “Hormones” Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.
2 citations
,
August 2023 in “Aesthetic Surgery Journal” RHA fillers are effective and safe for treating nasolabial folds in people of color.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
19 citations
,
September 2006 in “Journal of Pediatric Gastroenterology and Nutrition” Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.
15 citations
,
December 2014 in “Dermatology and therapy” Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
November 2024 in “International Journal of Research in Dermatology” SesZen-BioTM improves skin health and reduces signs of aging.
16 citations
,
November 2020 in “Research Square (Research Square)” Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
100 citations
,
March 1973 in “American Journal of Cardiology” Minoxidil effectively lowers blood pressure without major side effects.
1 citations
,
April 2024 in “Skin research and technology” Topical rosuvastatin and melatonin creams significantly reduce psoriasis severity and are safe.
12 citations
,
July 1979 in “International Journal of Dermatology” A patient with zinc depletion improved after zinc supplementation during parenteral nutrition.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology”
117 citations
,
February 2017 in “American Journal of Clinical Dermatology” Oral spironolactone's effectiveness for adult female acne is not well-supported by strong evidence.
3 citations
,
August 2022 in “JAAD case reports” A woman developed swelling in her body after taking low-dose oral minoxidil for hair loss, but it resolved after stopping the medication.
62 citations
,
April 2002 in “Journal of the American Academy of Dermatology” Sulfasalazine may help regrow hair in severe alopecia areata cases.
July 2025 in “Journal of Investigative Dermatology” 1 citations
,
September 2023 in “Journal of the American Academy of Dermatology”
1 citations
,
May 2025 in “The Journal of Rheumatology” Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Ixekizumab effectively treated severe psoriasis and hair loss in a patient.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
1 citations
,
September 2025 in “Medicina Moderna - Modern Medicine” Combining lifestyle changes with personalized medication is crucial for better managing obesity in PCOS.
1 citations
,
July 2010 in “PubMed”
6 citations
,
February 1996 in “Clinical Pharmacology & Therapeutics” Scale created to measure hair loss in men and women; MK-386 reduces acne; Niaspan treats dyslipidemia; minoxidil increases heart rate.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.